Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial

BACKGROUND: Oral direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) became government subsidized in Australia in March 2016, bringing the interferon era to a close. The ideal monitoring schedule for patients receiving DAAs is unclear. METHODS: This study is a randomized controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, J S, Young, M, Marshall, C, Tate-Baker, J, Madison, M, Sharma, S, Silva, C, Jones, T, Davies, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025718/
https://www.ncbi.nlm.nih.gov/pubmed/32083146
http://dx.doi.org/10.1093/ofid/ofaa022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025718/
https://www.ncbi.nlm.nih.gov/pubmed/32083146
http://dx.doi.org/10.1093/ofid/ofaa022

Ejemplares similares